These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 30753849)

  • 1. Aspirin in people with diabetes: Time to clean up the prescription list?
    Vouillarmet J; Aboyans V
    Diabetes Res Clin Pract; 2019 Mar; 149():208-209. PubMed ID: 30753849
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aspirin for Primary Cardiovascular Risk Prevention and Beyond in Diabetes Mellitus.
    Capodanno D; Angiolillo DJ
    Circulation; 2016 Nov; 134(20):1579-1594. PubMed ID: 27729421
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effective recruitment methods for a large randomised trial in people with diabetes: A Study of Cardiovascular Events iN Diabetes (ASCEND).
    Aung T; Haynes R; Barton J; Cox J; Murawska A; Murphy K; Lay M; Armitage J; Bowman L;
    Trials; 2016 Jun; 17(1):286. PubMed ID: 27296091
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aspirin for Primary Prevention of Cardiovascular Disease in Diabetes: a Review of the Evidence.
    Al-Sofiani ME; Derenbecker R; Quartuccio M; Kalyani RR
    Curr Diab Rep; 2019 Sep; 19(10):107. PubMed ID: 31544224
    [TBL] [Abstract][Full Text] [Related]  

  • 5. What have we learned about using aspirin for primary prevention from the ASCEND and ARRIVE trials?
    Tousoulis D
    Cardiovasc Res; 2019 Feb; 115(2):e15-e16. PubMed ID: 30668678
    [No Abstract]   [Full Text] [Related]  

  • 6. ASCEND: A Study of Cardiovascular Events iN Diabetes: Characteristics of a randomized trial of aspirin and of omega-3 fatty acid supplementation in 15,480 people with diabetes.
    Bowman L; Mafham M; Stevens W; Haynes R; Aung T; Chen F; Buck G; Collins R; Armitage J;
    Am Heart J; 2018 Apr; 198():135-144. PubMed ID: 29653635
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aspirin therapy and primary prevention of cardiovascular disease in diabetes mellitus.
    Younis N; Williams S; Soran H
    Diabetes Obes Metab; 2009 Nov; 11(11):997-1000. PubMed ID: 19531055
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aspirin and the Primary Prevention of Cardiovascular Diseases: An Approach Based on Individualized, Integrated Estimation of Risk.
    Volpe M; Battistoni A; Gallo G; Coluccia R; De Caterina R
    High Blood Press Cardiovasc Prev; 2017 Sep; 24(3):331-339. PubMed ID: 28573479
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Review of guidelines on primary prevention of cardiovascular disease with aspirin: how much evidence is needed to turn a tanker?
    Matthys F; De Backer T; De Backer G; Stichele RV
    Eur J Prev Cardiol; 2014 Mar; 21(3):354-65. PubMed ID: 23610452
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low-Dose Aspirin for Primary Prevention of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus: 10-Year Follow-Up of a Randomized Controlled Trial.
    Saito Y; Okada S; Ogawa H; Soejima H; Sakuma M; Nakayama M; Doi N; Jinnouchi H; Waki M; Masuda I; Morimoto T;
    Circulation; 2017 Feb; 135(7):659-670. PubMed ID: 27881565
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aspirin for primary prevention of cardiovascular events: meta-analysis of randomized controlled trials and subgroup analysis by sex and diabetes status.
    Xie M; Shan Z; Zhang Y; Chen S; Yang W; Bao W; Rong Y; Yu X; Hu FB; Liu L
    PLoS One; 2014; 9(10):e90286. PubMed ID: 25360605
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aspirin in primary prevention for patients with diabetes: Still a matter of debate.
    Bonaventura A; Liberale L; Montecucco F
    Eur J Clin Invest; 2018 Oct; 48(10):e13001. PubMed ID: 30011059
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aspirin for Primary Prevention of Atherosclerotic Cardiovascular Disease: Advances in Diagnosis and Treatment.
    Mora S; Manson JE
    JAMA Intern Med; 2016 Aug; 176(8):1195-204. PubMed ID: 27322595
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aspirin for CV prevention -- for which patients?
    Jackson AN; Hume AL
    J Fam Pract; 2011 Sep; 60(9):518-23. PubMed ID: 21901177
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Should we treat all diabetic patients with aspirin in primary prevention?].
    Righetti A; De Moerloose P; Philippe J
    Rev Med Suisse; 2005 Jun; 1(22):1500-4. PubMed ID: 16025889
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Questions and answers on the use of aspirin for primary prevention of cardiovascular disease in diabetes.
    Cavallari I; Nobile E; De Filippis A; Veneziano F; Maddaloni E; Ussia GP; Grigioni F
    Diabetes Res Clin Pract; 2022 Sep; 191():110043. PubMed ID: 35985427
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low-dose aspirin therapy for cardiovascular prevention: quantification and consequences of poor compliance or discontinuation.
    Herlitz J; Tóth PP; Naesdal J
    Am J Cardiovasc Drugs; 2010; 10(2):125-41. PubMed ID: 20334450
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aspirin in the primary prevention of cardiovascular disease in diabetes mellitus: A new perspective.
    Rocca B; Patrono C
    Diabetes Res Clin Pract; 2020 Feb; 160():108008. PubMed ID: 31926190
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aspirin for primary prevention of coronary heart disease: safety and absolute benefit related to coronary risk derived from meta-analysis of randomised trials.
    Sanmuganathan PS; Ghahramani P; Jackson PR; Wallis EJ; Ramsay LE
    Heart; 2001 Mar; 85(3):265-71. PubMed ID: 11179262
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low-dose aspirin for primary prevention of cardiovascular events in patients with diabetes: Benefit or risk?
    Leggio M; Bendini MG; Caldarone E; Lombardi M; Severi P; D'Emidio S; Stavri DC; Armeni M; Bravi V; Mazza A
    Diabetes Metab; 2018 Jun; 44(3):217-225. PubMed ID: 29257747
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.